These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34171441)

  • 41. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
    Komamine M; Kajiyama K; Ishiguro C; Uyama Y
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients.
    Yang CY; Lin WA; Su PF; Li LJ; Yang CT; Ou HT; Kuo S
    Clin Pharmacol Ther; 2021 Mar; 109(3):772-781. PubMed ID: 32978779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis.
    Zhang X; Zhao Q
    J Hypertens; 2016 Feb; 34(2):167-75. PubMed ID: 26682782
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral combination therapy in primary care.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
    Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
    Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical effectiveness of second-line antihyperglycemic drugs on major adverse cardiovascular events: An emulation of a target trial.
    Siriyotha S; Lukkunaprasit T; Angkananard T; Looareesuwan P; McKay GJ; Attia J; Thakkinstian A
    Front Endocrinol (Lausanne); 2023; 14():1094221. PubMed ID: 36793285
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example.
    Dong YH; Wang SV; Gagne JJ; Wu LC; Chang CH
    Value Health; 2020 Feb; 23(2):217-226. PubMed ID: 32113627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
    Bain S; Druyts E; Balijepalli C; Baxter CA; Currie CJ; Das R; Donnelly R; Khunti K; Langerman H; Leigh P; Siliman G; Thorlund K; Toor K; Vora J; Mills EJ
    Diabetes Obes Metab; 2017 Mar; 19(3):329-335. PubMed ID: 27862902
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
    Dai X; Wang H; Jing Z; Fu P
    Curr Med Res Opin; 2014 Sep; 30(9):1777-86. PubMed ID: 24805140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study.
    Chin HJ; Nam JH; Lee EK; Shin JY
    Medicine (Baltimore); 2017 Jun; 96(25):e7213. PubMed ID: 28640111
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
    Sicras-Mainar A; Navarro-Artieda R
    Rev Peru Med Exp Salud Publica; 2014; 31(4):626-34. PubMed ID: 25597711
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States.
    Tan X; Yang L; Khunti K; Zhang R; Zhang Y; Rajpathak S; Yu M
    Diabetes Obes Metab; 2021 Oct; 23(10):2251-2260. PubMed ID: 34132017
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis.
    Farah D; Leme GM; Eliaschewitz FG; Fonseca MCM
    Diabetes Res Clin Pract; 2019 Mar; 149():47-63. PubMed ID: 30710655
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
    Jil M; Rajnikant M; Richard D; Iskandar I
    Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. What to add in with metformin in type 2 diabetes?
    Petrie JR; Adler A; Vella S
    QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
    Noh Y; Jeon SM; Shin S
    Int J Cancer; 2019 Apr; 144(7):1530-1539. PubMed ID: 30229901
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.